Acurx Pharmaceuticals announced that the FDA has conditionally accepted the proprietary name CIFBEZY for its lead antibiotic candidate, ibezapolstat, which is being developed to treat and reduce recurrence of Clostridioides difficile infection (CDI). The U.S. Patent and Trademark Office has also allowed the trademark application for CIFBEZY, securing intellectual property rights. This milestone supports Acurx's preparation to advance ibezapolstat into international Phase 3 clinical trials and eventual commercialization, aiming to offer a novel treatment that could reduce CDI recurrence with a single antibiotic. The company plans to submit the final FDA review request for the brand name during the NDA marketing application.
Meta is facing a significant legal trial in California led by Attorney General Rob Bonta, involving 29 states accusing the company of fostering addictive behavior in teens and violating children’s privacy laws. This case follows a recent $1 billion l...
Cigna Group remains a strong buy with shares trading 28% below their fair value, supported by double-digit adjusted EPS growth. Key growth drivers include the Accredo and AI-powered Pharmacy Forward platforms, which are expected to boost revenue and ...
Goldgroup Mining completed over 25,700 meters of drilling at its Don David Gold Mine in Oaxaca, Mexico, focusing on infill and expansion at the Arista and Alta Gracia underground mines. The results reveal significant gold and silver mineralization, s...
The SPDR EURO STOXX 50 ETF (FEZ) is recommended as a core portfolio holding due to its lower concentration risk compared to the S&P 500 and true diversification benefits. European equities in FEZ benefit from positive sector momentum and reasonable v...
The First Trust Nasdaq Semiconductor ETF (FTXL) is well positioned to benefit from the ongoing buildout of AI infrastructure, driven by demand for CPUs and memory over GPUs. Key holdings like Intel, AMD, Broadcom, and Micron make up 36% of the fund a...
